Last 48 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 10.79 | — | 15.85 | 4.26 | 3.02 | — | — | — | — | — | — | — | — | — | — | — | 0.28 | 1.49 | 6.25 | — | 0.36 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -23.2% | — | — | — | — | |
| P/S Ratio | 14.16 | 9.67 | 7.47 | 24.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 16.67 | 5.32 | 1.66 | — | — | — | 16.91 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -90.2% | — | — | — | — | |
| P/FCF | — | 26.26 | 51.92 | — | — | — | — | — | — | — | — | — | — | — | — | 0.42 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 84.67 | 874.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 16.39 | 5.51 | 4.03 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 12.5% | 97.2% | 91.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 98.8% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -0.4% | |
| Operating Margin | — | 12.5% | 0.3% | -176.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 126.1% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +139.6% | |
| Net Margin | — | -159.6% | 46.4% | 566.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -351.3% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -0.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | -1151.3% | -98.9% | -47.9% | 654.0% | — | — | -350.2% | 1180.1% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +86.3% | -44.6% | — | — | — | — | |
| ROA | -1.1% | -21.4% | 4.6% | 18.3% | 33.8% | -16.0% | -11.7% | -13.1% | -10.6% | -9.6% | -14.1% | -9.1% | -2.1% | -7.4% | -6.9% | -5.9% | 24.6% | -4.3% | -8.6% | -8.4% | 103.4% |
| — | -34.0% | +139.6% | +240.3% | +418.3% | -66.3% | +17.4% | -43.3% | -410.3% | -30.1% | -105.9% | -55.7% | -108.5% | -70.2% | +20.5% | +30.1% | -76.3% | +74.3% | +53.7% | +59.1% | +666.2% | |
| ROIC | -142.5% | 5.2% | 0.0% | -7.4% | -56.7% | — | -32.1% | -24.0% | -71.5% | -14.3% | -12.4% | -8.0% | -9.5% | -9.3% | -6.1% | -5.7% | -10.6% | -17.0% | -9.0% | -8.8% | -43.3% |
| — | — | +100.1% | +69.3% | +20.8% | — | -159.6% | -199.0% | -650.4% | -53.9% | -101.7% | -40.3% | +10.1% | +45.4% | +31.8% | +34.7% | +75.5% | +52.1% | +73.4% | +67.7% | -152.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 22.77 | 8.51 | 3.99 | — | — | — | 14.63 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -72.7% | — | — | — | — | |
| Debt / EBITDA | — | 41.59 | 313.76 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.76 | 2.27 | 1.95 | 3.03 | 2.76 | 0.89 | 0.81 | 1.16 | 1.69 | 2.96 | 3.41 | 4.76 | 4.09 | 2.39 | 2.71 | 3.00 | 3.25 | 7.30 | 5.01 | 6.00 | 4.79 |
| — | +154.9% | +139.5% | +162.5% | +63.8% | -70.0% | -76.1% | -75.7% | -58.7% | +24.2% | +26.0% | +58.8% | +25.8% | -67.3% | -45.9% | -50.0% | -32.1% | +242.3% | +112.4% | +96.5% | +16.3% | |
| Quick Ratio | 2.76 | 2.26 | 1.94 | 3.03 | 2.76 | 0.89 | 0.81 | 1.16 | 1.69 | 2.96 | 3.41 | 4.76 | 4.09 | 2.39 | 2.71 | 3.00 | 3.25 | 7.30 | 5.01 | 6.00 | 4.79 |
| — | +154.2% | +138.4% | +162.3% | +63.8% | -70.0% | -76.1% | -75.7% | -58.7% | +24.2% | +26.0% | +58.8% | +25.8% | -67.3% | -45.9% | -50.0% | -32.1% | +245.0% | +114.3% | +98.3% | +17.3% | |
| Interest Coverage | — | -9.25 | 1.88 | 9.70 | 9.39 | — | -1724.93 | -9.28 | -10.50 | -8.16 | -6.07 | -4.33 | -8.87 | -5.53 | -4.58 | -4.00 | -4.83 | -10.11 | -7.46 | -6.99 | -20.25 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OMER stock.
Omeros Corporation's current P/E is 10.8x. The average P/E over the last 3 quarters is 7.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Omeros Corporation's business trajectory between earnings reports.